Sutro Biopharma

Q2 FY2026 EarningsQ2 FY26 missed consensus on the top line with revenue of $9.8M vs. $11.0M expected, primarily due to timing of collaboration milestones. GAAP EPS of -$2.33 was in-line with the consensus mid-point of -$2.33, despite a larger-than-expected net loss, supported by a weighted-average share count increase. Management extended the cash runway guidance into Q2 2028, backed by $164.3M in liquidity and positive early clinical signals from the STRO-004 Phase 1 study.